← Back to Clinical Trials
Recruiting NCT02558699

NCT02558699 Clinical Usefulness of Virtual Ablation Guided Catheter Ablation of Atrial Fibrillation: Virtual Rotor Mapping and Catheter Ablation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02558699
Status Recruiting
Phase
Sponsor Yonsei University
Condition Paroxysmal Atrial Fibrillation
Study Type INTERVENTIONAL
Enrollment 110 participants
Start Date 2018-08-24
Primary Completion 2027-12-31

Trial Parameters

Condition Paroxysmal Atrial Fibrillation
Sponsor Yonsei University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 110
Sex ALL
Min Age 19 Years
Max Age 80 Years
Start Date 2018-08-24
Completion 2027-12-31
Interventions
physician's personal experienceVirtual rotor mapping

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Radiofrequency catheter ablation is effective in the treatment of patients with paroxysmal atrial fibrillation. In order to reduce the recurrence rate after catheter ablation, the investigators propose to apply 'virtual' ablation on patient-specific atria by simulating 3D atrial computer model. The investigators will conduct virtual rotor mapping in the patient specific atrial model. Then, the investigators will compare the clinical outcome of conventional circumferential pulmonary vein isolation and additional rotor ablation guided by virtual rotor mapping.

Eligibility Criteria

Inclusion Criteria: * AF patient age 19\~80 * Diagnosis of AF patients who performed catheter ablation of atrial fibrillation due to uncontrolled pulse rate by anti-arrhythmic drug therapy. Exclusion Criteria: * AF patients who have severe heart deformations or vascular disease. * The patient who have renal disease of eGFR\<30mL/min * The patients who had been performed catheter ablation of atrial ablation and MAZE. * The patients who missed out to recording of 3D CT, echo and electrocardiography. * the patient have experienced major hemorrhagic complication * The patient have experienced ischemic cerebral infarction more 2 times * The patient who have risk of ischemic cerebral infarction (CHA2DS2-VASc Score \>5)

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology